Side-by-side · Research reference

TesofensinevsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3AUTO-DRAFTED10/40 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Tesofensine

Vesugen

Primary target

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Tesofensine

Vesugen

Standard dose

0.25–0.5 mg / dayAstrup 2008

—

Frequency

Once daily, morning

Not specified in available literature

Lower / starter dose

0.125 mg / day

—

Evidence basis

Phase 2b + ongoing Phase 3Astrup 2008

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

24 weeks per studied cycle

Case series report treatment courses in elderly arterial insufficiency

Form

Oral capsule

—

Timing

Morning to avoid sleep disruption

—

Half-life

~9 days (very long)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

Tesofensine

Vesugen

Heart rate / BP

Dose-dependent ↑ HR + BPAstrup 2008

—

Insomnia

Dose-related; mitigate with morning timing

—

Dry mouth

Common

—

Nausea

Common

—

Mood changes

Anxiety / agitation possible

—

Cardiovascular events

Phase 3 trial monitoring; not yet FDA-cleared

—

Pregnancy / OB

Contraindicated

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Vesugen

—

Relative Contraindications

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Tesofensine

Vesugen

1. Form

Oral capsule (investigational; not commercial).

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Administration

Swallow whole with water, morning only.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Morning to mitigate insomnia. Do not dose evening.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Caveat

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

—

06Stack Synergy

Tesofensine

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)